Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials | Zendy

SerbanDan Costa | Zendy; Christian Jackisch | Zendy; Christoph Thomssen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials

Author(s) -

SerbanDan Costa,

Christian Jackisch,

Christoph Thomssen

Publication year - 2010

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000285778

Subject(s) - lapatinib , medicine , breast cancer , oncology , adjuvant , cardiotoxicity , tyrosine kinase inhibitor , trastuzumab , refractory (planetary science) , cancer , clinical trial , neoadjuvant therapy , chemotherapy , physics , astrobiology

SUMMARY: Lapatinib is potentially an ideal therapy for the adjuvant and neoadjuvant treatment of women with breast cancer due to its convenience of use (oral, once-daily administration) and because it has shown activity in the first-line and refractory metastatic settings. Furthermore, the dual tyrosine kinase inhibitor appears to have a low incidence of cardiotoxicity, and may decrease the rate of later brain metastases. Therefore, several cooperative groups and academic centers have initiated trials investigating lapatinib in the treatment of early-stage ErbB2 (HER2)-overexpressing breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research